Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients

Wspolczesna Onkologia

Volumn 17, Issue 1, 2013, Pages 68-72

  Tulek, Baykal ^a   Koylu, Habibe ^a   Kanat, Fikret ^a   Arslan, Ugur ^a   Ozer, Faruk ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b Farabi Klinik   (Turkey)

Author keywords

C reactive protein; Inflammation; Non small cell lung cancer; Procalcitonin

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING; TUMOR VOLUME;

EID: 84876219041     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.33777     Document Type: Article

References (37)

1. Marnell L, Mold C, Du Clos TW. C-reactive protein: Ligands, receptors and role in inflammation. Clin Immunol 2005; 117: 104-11.
2. Putinati S, Trevisani L, Gualandi M, Guerra G, Rossi MR, Sartori S, Potena A. Pulmonary infections in lung cancer patients at diagnosis. Lung Cancer 1994; 11: 243-9.
3. Berghmans T, Sculier JP, Klastersky J. A prospective study of infections in lung cancer patients admitted to the hospital. Chest 2003; 124: 114-20.
4. Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum C-reactive protein are associated with nonsmall cell lung cancer. Lung Cancer 2006; 53: 97-101.
5. Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim DJ, Ahn SV, Chung KY. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer 2009; 63: 106-10.
6. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002; 87: 264-7.
7. Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, Enomoto Y, Onitsuka T. Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 2007; 27: 3001-4.
8. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605-8.
9. Maruna P, Nedelníková K, Gürlich R. Physiology and genetics of procalcitonin. Physiol Res 2000; 49 Suppl 1: S57-61.
10. Nijsten MW, Olinga P, The TH, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28: 458-61.
11. Schröder J, Staubach KH, Zabel P, Stüber F, Kremer B. Procalcitonin as amarker of severity in septic shock. Langenbecks Arch Surg 1999; 384: 33-8.
12. Schüttrumpf S, Binder L, Hagemann T, Berkovic D, Trümper L, Binder C. Procalcitonin: A useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol 2003; 82: 98-103.
13. Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 2006; 43: 468-73.
14. Matzaraki V, Alexandraki KI, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007; 40: 336-42.
15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
16. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 539-45.
17. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brünner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000; 7: 617-23.
18. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103: 1856-64.
19. Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer 2006; 94: 781-4.
20. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002; 122: 1037-57.
21. Wyrobiec G, Rokicki W, Stȩplewska K, Kasperczyk J, Stȩpień-Wyrobiec O, Sabat D, Helewski K. Protein p53 in non-small lung carcinomas. Kardiochir Torakochir Pol 2011; 8: 77-82.
22. Fernando HC, Goldstraw P. The accuracy of clinical evaluative intrathoracic staging in lung cancer as assessed by postsurgical pathologic staging. Cancer 1990; 65: 2503-6.
23. Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR, McNeil BJ. CT and MR imaging in staging non-small cell bronchoge-nic carcinoma: Report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178: 705-13.
24. Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced nonsmall cell lung cancer. Onkologie 2008; 31: 665-70.
25. Berghmans T, Dusart M, Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3: 6-12.
26. Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, Poncelet AJ. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008; 33: 819-23.
27. Gonzalez-Stawinski GV, Lemaire A, Merchant F, O'Halloran E, Coleman RE, Harpole DH, D'Amico TA. A comparative analysis of positron emission tomography and mediastinoscopy in staging nonsmall cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1900-5.
28. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004; 125: 1413-23.
29. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126: 1943-51.
30. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003; 31: 1737-41.
31. Meisner M, Tschaikowsky K, Palmaers T, Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 1999; 3: 45-50.
32. Penel N, Fournier C, Clisant S, N'Guyen M. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer 2004; 12: 593-8.
33. Giovanella L, Suriano S, Ricci R, Ravani P, Ceriani L. Circulating procalcitonin in aseptic carcinoma patients: A specificity study with (18)Ffluorodeoxyglucose positron-emission tomography/computed tomography as benchmark. Clin Chem Lab Med 2010; 48: 1163-5.
34. Ghillani PP, Motté P, Troalen F, et al. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. Cancer Res 1989; 49: 6845-51.
35. Perlin E, Bang KM, Shah A, Hursey PD, Whittingham WL, Hashmi K, Campbell L, Kassim OO. The impact of pulmonary infections on the survival of lung cancer patients. Cancer 1990; 66: 593-6.
36. Soyseth V, Benth JS, Stavem K. The association between hospitalisation for pneumonia and the diagnosis of lung cancer. Lung Cancer 2007; 57: 152-8.
37. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, Arndt G, Lode H. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003; 21: 939-43.